Australian Streptokinase Trial (ASK)
A multicenter randomized controlled trial will be conducted to test the hypothesis that the intravenous administration of the thrombolytic agent streptokinase within 4 h of the onset of acute ischemic stroke will result in a significant reduction in subsequent morbidity and mortality. Six hundred eligible patients from 20 to 30 centers will be randomized to receive either 1.5 × 106 units of streptokinase or placebo infused over 60 min. Patients will be accrued over a 3-year period and the results analyzed on an intention-to-treat basis. Primary end-points will be death and 3-month disability on Barthel index or, if no significant difference in death rates between treatment and placebo groups exists, the primary end-point will be improvement in Modified Canadian Neurological Score (MCNS) among the living.
KeywordsPlacebo Aspirin Heparin Warfarin Neurol
Unable to display preview. Download preview PDF.